{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:10:22Z","timestamp":1791432622827,"version":"4.3.3"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40263-022-00979-1","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T12:02:57Z","timestamp":1671624177000},"page":"13-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Treatment Outcomes of Newly Diagnosed Epilepsy: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8601-3686","authenticated-orcid":false,"given":"Mubeen","family":"Janmohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Hakeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyi","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhailah","family":"Hakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Perucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence J.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Antonic-Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7310-276X","authenticated-orcid":false,"given":"Patrick","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"key":"979_CR1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","volume":"88","author":"KM Fiest","year":"2017","unstructured":"Fiest KM, Sauro KM, Wiebe S, Patten SB, Kwon C-S, Dykeman J, et al. Prevalence and incidence of epilepsy. Neurology. 2017;88:296\u2013303.","journal-title":"Neurology"},{"key":"979_CR2","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/brain\/awab401","volume":"145","author":"HD Simpson","year":"2022","unstructured":"Simpson HD, Foster E, Ademi Z, Lawn N, Brodie MJ, Chen Z, et al. Markov modelling of treatment response in a 30-year cohort study of newly diagnosed epilepsy. Brain. 2022;145:1326\u201337.","journal-title":"Brain"},{"key":"979_CR3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","volume":"75","author":"Z Chen","year":"2018","unstructured":"Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75:279.","journal-title":"JAMA Neurol"},{"key":"979_CR4","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","volume":"369","author":"AG Marson","year":"2007","unstructured":"Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1016\u201326.","journal-title":"Lancet"},{"key":"979_CR5","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","volume":"369","author":"AG Marson","year":"2007","unstructured":"Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1000\u201315.","journal-title":"Lancet"},{"key":"979_CR6","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107880","volume":"117","author":"S Sharma","year":"2021","unstructured":"Sharma S, Chen Z, Rychkova M, Dunne J, Lee J, Lawn N, et al. Short- and long-term outcomes of immediate and delayed treatment in epilepsy diagnosed after one or multiple seizures. Epilepsy Behav. 2021;117: 107880.","journal-title":"Epilepsy Behav"},{"key":"979_CR7","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3182563b19","volume":"78","author":"MJ Brodie","year":"2012","unstructured":"Brodie MJ, Barry SJE, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78:1548\u201354.","journal-title":"Neurology"},{"key":"979_CR8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/jnnp-2015-312314","volume":"87","author":"GS Bell","year":"2016","unstructured":"Bell GS, Neligan A, Giavasi C, Keezer MR, Novy J, Peacock JL, et al. Outcome of seizures in the general population after 25 years: a prospective follow-up, observational cohort study. J Neurol Neurosurg Psychiatry. 2016;87:843\u201350.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"979_CR9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/epi.12862","volume":"56","author":"AT Berg","year":"2015","unstructured":"Berg AT, Rychlik K. The course of childhood-onset epilepsy over the first two decades: a prospective, longitudinal study. Epilepsia. 2015;56:40\u20138.","journal-title":"Epilepsia"},{"key":"979_CR10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1528-1167.2012.03429.x","volume":"53","author":"A Geerts","year":"2012","unstructured":"Geerts A, Brouwer O, Stroink H, van Donselaar C, Peters B, Peeters E, et al. Onset of intractability and its course over time: the Dutch study of epilepsy in childhood. Epilepsia. 2012;53:741\u201351.","journal-title":"Epilepsia"},{"key":"979_CR11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","volume":"342","author":"P Kwan","year":"2000","unstructured":"Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314\u20139.","journal-title":"N Engl J Med"},{"key":"979_CR12","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S1474-4422(20)30035-1","volume":"19","author":"E Perucca","year":"2020","unstructured":"Perucca E, Brodie MJ, Kwan P, Tomson T. 30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol. 2020;19:544\u201356.","journal-title":"Lancet Neurol"},{"key":"979_CR13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12883-015-0494-y","volume":"15","author":"K Allers","year":"2015","unstructured":"Allers K, Essue BM, Hackett ML, Muhunthan J, Anderson CS, Pickles K, et al. The economic impact of epilepsy: a systematic review. BMC Neurol. 2015;15:245.","journal-title":"BMC Neurol"},{"key":"979_CR14","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies: definition of drug resistant epilepsy. Epilepsia. 2010;51:1069\u201377.","journal-title":"Epilepsia"},{"key":"979_CR15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eplepsyres.2016.08.023","volume":"127","author":"E Bruun","year":"2016","unstructured":"Bruun E, K\u00e4lvi\u00e4inen R, Ker\u00e4nen T. Outcome of initial antiepileptic drug treatment in elderly patients with newly diagnosed epilepsy. Epilepsy Res. 2016;127:60\u20135.","journal-title":"Epilepsy Res"},{"key":"979_CR16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.seizure.2016.07.016","volume":"41","author":"A Ashmawi","year":"2016","unstructured":"Ashmawi A, Hosny H, Abdelalim A, Bianchi E, Beghi E. The long-term prognosis of newly diagnosed epilepsy in Egypt: a retrospective cohort study from an epilepsy center in Greater Cairo. Seizure. 2016;41:86\u201395.","journal-title":"Seizure."},{"key":"979_CR17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1212\/01.WNL.0000073543.63457.0A","volume":"61","author":"DP Shackleton","year":"2003","unstructured":"Shackleton DP, Kasteleijn-Nolst Trenite DGA, de Craen AJM, Vandenbroucke JP, Westendorp RGJ. Living with epilepsy: long-term prognosis and psychosocial outcomes. Neurology. 2003;61:64\u201370.","journal-title":"Neurology"},{"key":"979_CR18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2377-13-116","volume":"13","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Yu N, Su L, Di Q. A prospective cohort study of prognosis for newly diagnosed epilepsy in east China. BMC Neurol. 2013;13:116.","journal-title":"BMC Neurol"},{"key":"979_CR19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1600-0404.2012.01711.x","volume":"127","author":"L Su","year":"2013","unstructured":"Su L, Di Q, Kwan P, Yu N, Zhang Y, Hu Y, et al. Prediction for relapse and prognosis of newly diagnosed epilepsy. Acta Neurol Scand. 2013;127:141\u20137.","journal-title":"Acta Neurol Scand"},{"key":"979_CR20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.yebeh.2019.04.006","volume":"96","author":"L Yao","year":"2019","unstructured":"Yao L, Cai M, Chen Y, Shen C, Shi L, Guo Y. Prediction of antiepileptic drug treatment outcomes of patients with newly diagnosed epilepsy by machine learning. Epilepsy Behav. 2019;96:92\u20137.","journal-title":"Epilepsy Behav"},{"key":"979_CR21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1528-1167.2009.02141.x","volume":"51","author":"A Del Felice","year":"2010","unstructured":"Del Felice A, Beghi E, Boero G, La Neve A, Bogliun G, De Palo A, et al. Early versus late remission in a cohort of patients with newly diagnosed epilepsy. Epilepsia. 2010;51:37\u201342.","journal-title":"Epilepsia"},{"key":"979_CR22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.seizure.2016.02.007","volume":"37","author":"C Shen","year":"2016","unstructured":"Shen C, Du Y, Lu R, Zhang Y, Jin B, Ding Y, et al. Factors predictive of late remission in a cohort of Chinese patients with newly diagnosed epilepsy. Seizure. 2016;37:20\u20134.","journal-title":"Seizure."},{"key":"979_CR23","volume":"9","author":"G Powell","year":"2019","unstructured":"Powell G, Logan J, Kiri V, Borghs S. Trends in antiepileptic drug treatment and effectiveness in clinical practice in England from 2003 to 2016: a retrospective cohort study using electronic medical records. BMJ Open. 2019;9: e032551.","journal-title":"BMJ Open"},{"key":"979_CR24","unstructured":"Deeks J, Higgins J, Altman D. Chapter 10: analysing data and undertaking meta-analyses. Version 6.3. Cochrane; 2022. https:\/\/training.cochrane.org\/handbook\/current\/chapter-10. Accessed 3 Nov 2022."},{"key":"979_CR25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","volume":"72","author":"VN Nyaga","year":"2014","unstructured":"Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014;72:39.","journal-title":"Arch Public Health."},{"key":"979_CR26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","volume":"55","author":"RS Fisher","year":"2014","unstructured":"Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475\u201382.","journal-title":"Epilepsia"},{"key":"979_CR27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.seizure.2017.02.018","volume":"47","author":"Y Jiang","year":"2017","unstructured":"Jiang Y, Yuan F, Yang F, Sun X, Yang X, Song L, et al. Prognostic analysis for short- and long-term outcomes of newly diagnosed epilepsy. Seizure. 2017;47:92\u20138.","journal-title":"Seizure."},{"key":"979_CR28","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/epi.14643","volume":"60","author":"L-O Brorson","year":"2019","unstructured":"Brorson L-O, Eriksson M, Blomberg K, Stenninger E. Fifty years\u2019 follow-up of childhood epilepsy: medical outcome, morbidity, and medication. Epilepsia. 2019;60:381\u201392.","journal-title":"Epilepsia"},{"key":"979_CR29","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.yebeh.2009.08.029","volume":"16","author":"M Sillanpaa","year":"2009","unstructured":"Sillanpaa M, Schmidt D. Delayed time to first remission identifies poor long-term drug response of childhood-onset epilepsy: a prospective population-based study. Epilepsy Behav. 2009;16:507\u201311.","journal-title":"Epilepsy Behav"},{"key":"979_CR30","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0387-7604(00)00121-2","volume":"22","author":"H Wakamoto","year":"2000","unstructured":"Wakamoto H, Nagao H, Hayashi M, Morimoto T. Long-term medical, educational, and social prognoses of childhood-onset epilepsy: a population-based study in a rural district of Japan. Brain Dev. 2000;22:246\u201355.","journal-title":"Brain Dev"},{"key":"979_CR31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/088307389601100307","volume":"11","author":"E Hauser","year":"1996","unstructured":"Hauser E, Freilinger M, Seidl R, Groh C. Prognosis of childhood epilepsy in newly referred patients. J Child Neurol. 1996;11:201\u20134.","journal-title":"J Child Neurol"},{"key":"979_CR32","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/brain\/awn037","volume":"131","author":"M Sillanpaa","year":"2008","unstructured":"Sillanpaa M, Schmidt D. Seizure clustering during drug treatment affects seizure outcome and mortality of childhood-onset epilepsy. Brain. 2008;131:938\u201344.","journal-title":"Brain"},{"key":"979_CR33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1528-1167.2005.00309.x","volume":"46","author":"P Jallon","year":"2005","unstructured":"Jallon P, Latour P. Epidemiology of idiopathic generalized epilepsies. Epilepsia. 2005;46:10\u20134.","journal-title":"Epilepsia"},{"key":"979_CR34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1528-1157.43.s.3.3.x","volume":"43","author":"P Camfield","year":"2002","unstructured":"Camfield P, Camfield C. Epileptic syndromes in childhood: clinical features, outcomes, and treatment. Epilepsia. 2002;43:27\u201332.","journal-title":"Epilepsia"},{"key":"979_CR35","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1001\/jamaneurol.2022.2514","volume":"79","author":"H Hakeem","year":"2022","unstructured":"Hakeem H, Feng W, Chen Z, Choong J, Brodie MJ, Fong S-L, et al. Development and validation of a deep learning model for predicting treatment response in patients with newly diagnosed epilepsy. JAMA Neurol. 2022;79:986.","journal-title":"JAMA Neurol"},{"key":"979_CR36","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(21)00246-4","volume":"397","author":"A Marson","year":"2021","unstructured":"Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397:1375\u201386.","journal-title":"Lancet"},{"key":"979_CR37","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107871","volume":"117","author":"E Beghi","year":"2021","unstructured":"Beghi E, Beretta S, Colombo M, Bianchi E, Carone D, Zanchi C, et al. Discontinuation of antiseizure medications in seizure-free patients with long-term follow-up: patients\u2019 profile, seizure recurrence, and risk factors. Epilepsy Behav. 2021;117: 107871.","journal-title":"Epilepsy Behav"},{"key":"979_CR38","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/brain\/awu294","volume":"137","author":"AT Berg","year":"2014","unstructured":"Berg AT, Rychlik K, Levy SR, Testa FM. Complete remission of childhood-onset epilepsy: stability and prediction over two decades. Brain. 2014;137:3213\u201322.","journal-title":"Brain"},{"key":"979_CR39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1212\/WNL.46.1.41","volume":"46","author":"C Camfield","year":"1996","unstructured":"Camfield C, Camfield P, Gordon K, Dooley J. Does the number of seizures before treatment influence ease of control or remission of childhood epilepsy? Not if the number is 10 or less. Neurology. 1996;46:41\u20134.","journal-title":"Neurology"},{"key":"979_CR40","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107095","volume":"108","author":"O Henning","year":"2020","unstructured":"Henning O, Medalen TEM, Nakken KO, Lossius MI. How often do doctors discuss drug withdrawal with their seizure-free patients with epilepsy? Epilepsy Behav. 2020;108: 107095.","journal-title":"Epilepsy Behav"},{"key":"979_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14596","author":"L Kalilani","year":"2018","unstructured":"Kalilani L, Sun X, Pelgrims B, Noack-Rink M, Villanueva V. The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis. Epilepsia. 2018. https:\/\/doi.org\/10.1111\/epi.14596. (Accessed 17 Nov 2018).","journal-title":"Epilepsia"},{"key":"979_CR42","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1528-1167.2010.02546.x","volume":"51","author":"A Geerts","year":"2010","unstructured":"Geerts A, Arts WF, Stroink H, Peeters E, Brouwer O, Peters B, et al. Course and outcome of childhood epilepsy: a 15-year follow-up of the Dutch Study of Epilepsy in Childhood. Epilepsia. 2010;51:1189\u201397.","journal-title":"Epilepsia"},{"key":"979_CR43","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/jnnp-2019-320883","volume":"90","author":"E Beghi","year":"2019","unstructured":"Beghi E, Beretta S, Carone D, Zanchi C, Bianchi E, Pirovano M, et al. Prognostic patterns and predictors in epilepsy: a multicentre study (PRO-LONG). J Neurol Neurosurg Psychiatry. 2019;90:1276\u201385.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"979_CR44","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3389\/fneur.2017.00658","volume":"8","author":"L Xia","year":"2017","unstructured":"Xia L, Ou S, Pan S. Initial response to antiepileptic drugs in patients with newly diagnosed epilepsy as a predictor of long-term outcome. Front Neurol. 2017;8:658.","journal-title":"Front Neurol"},{"key":"979_CR45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.yebeh.2012.11.041","volume":"27","author":"AG Besocke","year":"2013","unstructured":"Besocke AG, Rosso B, Cristiano E, Valiensi SM, del Garc\u00eda MC, Gonorazky SE, et al. Outcome of newly-diagnosed epilepsy in older patients. Epilepsy Behav. 2013;27:29\u201335.","journal-title":"Epilepsy Behav"},{"key":"979_CR46","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1474-4422(12)70018-2","volume":"11","author":"L Bonnett","year":"2012","unstructured":"Bonnett L, Smith CT, Smith D, Williamson P, Chadwick D, Marson AG. Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial. Lancet Neurol. 2012;11:331\u201340.","journal-title":"Lancet Neurol"},{"key":"979_CR47","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.yebeh.2014.07.002","volume":"37","author":"L Huang","year":"2014","unstructured":"Huang L, Li S, He D, Bao W, Li L. A predictive risk model for medical intractability in epilepsy. Epilepsy Behav. 2014;37:282\u20136.","journal-title":"Epilepsy Behav"},{"key":"979_CR48","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1177\/08830738050200110701","volume":"20","author":"M Oskoui","year":"2005","unstructured":"Oskoui M, Webster RI, Zhang X, Shevell MI. Factors predictive of outcome in childhood epilepsy. J Child Neurol. 2005;20:898\u2013904.","journal-title":"J Child Neurol"},{"key":"979_CR49","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1212\/WNL.0000000000000147","volume":"82","author":"AC Modi","year":"2014","unstructured":"Modi AC, Rausch JR, Glauser TA. Early pediatric antiepileptic drug nonadherence is related to lower long-term seizure freedom. Neurology. 2014;82:671\u20133.","journal-title":"Neurology"},{"key":"979_CR50","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ane.12275","volume":"130","author":"OR Obiako","year":"2014","unstructured":"Obiako OR, Sheikh TL, Kehinde JA, Iwuozo EU, Ekele N, Elonu CC, et al. Factors affecting epilepsy treatment outcomes in Nigeria. Acta Neurol Scand. 2014;130:360\u20137.","journal-title":"Acta Neurol Scand"},{"key":"979_CR51","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1177\/0883073809334381","volume":"24","author":"E Simard-Tremblay","year":"2009","unstructured":"Simard-Tremblay E, Shevell M. A profile of adolescent-onset epilepsy. J Child Neurol. 2009;24:1243\u20139.","journal-title":"J Child Neurol"},{"key":"979_CR52","volume":"105","author":"ALF Caprara","year":"2020","unstructured":"Caprara ALF, Rissardo JP, Leite MTB, Silveira JOF, Jauris PGM, Arend J, et al. Course and prognosis of adult-onset epilepsy in Brazil: a cohort study. Epilepsy Behav. 2020;105: 106969.","journal-title":"Epilepsy Behav"},{"key":"979_CR53","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.seizure.2016.03.011","volume":"38","author":"C Huang","year":"2016","unstructured":"Huang C, Feng L, Li Y, Wang Y, Chi X, Wang W, et al. Clinical features and prognosis of epilepsy in the elderly in western China. Seizure. 2016;38:26\u201331.","journal-title":"Seizure."},{"key":"979_CR54","doi-asserted-by":"crossref","first-page":"16254","DOI":"10.1038\/s41598-019-52574-y","volume":"9","author":"K Gidey","year":"2019","unstructured":"Gidey K, Chelkeba L, Gemechu TD, Daba FB. Treatment response and predictors in patients with newly diagnosed epilepsy in Ethiopia: a retrospective cohort study. Sci Rep. 2019;9:16254.","journal-title":"Sci Rep"},{"key":"979_CR55","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1046\/j.1528-1157.2001.0420081025.x","volume":"42","author":"H Lindsten","year":"2002","unstructured":"Lindsten H, Stenlund H, Forsgren L. Remission of seizures in a population-based adult cohort with a newly diagnosed unprovoked epileptic seizure. Epilepsia. 2002;42:1025\u201330.","journal-title":"Epilepsia"},{"key":"979_CR56","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/ana.21806","volume":"67","author":"RAB Badawy","year":"2010","unstructured":"Badawy RAB, Macdonell RAL, Berkovic SF, Newton MR, Jackson GD. Predicting seizure control: cortical excitability and antiepileptic medication. Ann Neurol. 2010;67:64\u201373.","journal-title":"Ann Neurol"},{"key":"979_CR57","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1212\/WNL.0b013e3181f25b16","volume":"75","author":"S Petrovski","year":"2010","unstructured":"Petrovski S. Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients. Neurology. 2010;75:1015\u201321.","journal-title":"Neurology"},{"key":"979_CR58","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-4016","volume":"141","author":"KM Aaberg","year":"2018","unstructured":"Aaberg KM, Bakken IJ, Lossius MI, Lund S\u00f8raas C, Tallur KK, Stoltenberg C, et al. Short-term seizure outcomes in childhood epilepsy. Pediatrics. 2018;141: e20174016.","journal-title":"Pediatrics"},{"key":"979_CR59","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.seizure.2012.01.009","volume":"21","author":"J Ramos-Lizana","year":"2012","unstructured":"Ramos-Lizana J, Rodriguez-Lucenilla MI, Aguilera-L\u00f3pez P, Aguirre-Rodr\u00edguez J, Cassinello-Garc\u00eda E. A study of drug-resistant childhood epilepsy testing the new ILAE criteria. Seizure. 2012;21:266\u201372.","journal-title":"Seizure."},{"key":"979_CR60","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1111\/j.1528-1167.2012.03661.x","volume":"53","author":"KC Nickels","year":"2012","unstructured":"Nickels KC, Grossardt BR, Wirrell EC. Epilepsy-related mortality is low in children: a 30-year population-based study in Olmsted County. MN Epilepsia. 2012;53:2164\u201371.","journal-title":"MN. Epilepsia."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00979-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00979-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00979-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T16:09:41Z","timestamp":1673280581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00979-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["979"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00979-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,21]]},"assertion":[{"value":"30 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not receive any specific funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MJ and HH are supported by the Monash University RTP Stipend scholarship. PP is supported by the National Health and Medical Research Council (APP1163708), the Epilepsy Foundation, The University of Melbourne, Monash University, Brain Australia, the Weary Dunlop Medical Research Foundation, and the Norman Beischer Medical Research Foundation and has received speaker honoraria or consultancy fees to his institution from Chiesi, Eisai, LivaNova, Novartis, Sun Pharma, Supernus, and UCB Pharma, outside the submitted work. He is an Associate Editor for Epilepsia Open. TJO is supported by an NHMRC Investigator Grant (APP1176426) and his institution has received research grants, speaker honoraria, or consultancy fees from Chiesi, Eisai, UCB Pharma, Zynerba Pharmaceuticals, ES Pharmaceuticals, Supernus, and LivaNova, outside the submitted work. ZC is supported by an Early Career Fellowship from the National Health and Medical Research Council of Australia (GNT1156444), and he\/his institution has received consultancy fees and\/or research grants from Arvelle Therapeutics and UCB Pharma. PK is supported by a Medical Research Future Fund Practitioner Fellowship (MRF1136427). He\/his institution has received research grants, speaker honoraria, or consultancy fees from Chiesi, Eisai, UCB Pharma, and LivaNova, outside the submitted work. The other authors have no disclosures to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"No ethical approval was required for this study. All data were study-level characteristics and outcomes for a meta-analysis. We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data extracted have been made available in the online supplementary material. Further cohort data information can be obtained through request to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MJ was the first author involved in the design, systematic search protocol, conceptualization, screening, data extraction, quality rating, statistical contribution, and authoring of the manuscript. HH was involved in the screening, data extraction, quality rating, and editing of the manuscript. SO, LV, and SH were involved in the screening and editing of the manuscript. A-AB was involved in the design, quality rating, and editing of the manuscript. ZC was involved in the design, statistical analysis, and editing of the manuscript. PP and TO were involved in the editing of the manuscript. PK was the senior author in the conceptualizing, design, statistical contribution, and editing of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}